{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:34:09Z","timestamp":1790102049110,"version":"4.0.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI144036"],"award-info":[{"award-number":["K23AI144036"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["6U54CK000609"],"award-info":[{"award-number":["6U54CK000609"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["U54CK000601"],"award-info":[{"award-number":["U54CK000601"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.idc.2025.07.007","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:19:48Z","timestamp":1754911188000},"page":"663-683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Microbiome Therapeutics for Clostridioides difficile Infection"],"prefix":"10.1016","volume":"39","author":[{"given":"Christine W.","family":"Lucky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Medernach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie H.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Woodworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.idc.2025.07.007_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.17597","article-title":"Incidence and outcomes associated with clostridium difficile infections: a systematic review and meta-analysis","volume":"3","author":"Marra","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.idc.2025.07.007_bib2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1053\/j.gastro.2006.02.044","article-title":"Recurrent clostridium difficile","volume":"130","author":"Maroo","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idc.2025.07.007_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1469-0691.12046","article-title":"Can we identify patients at high risk of recurrent clostridium difficile infection?","volume":"18","author":"Kelly","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.idc.2025.07.007_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/antibiotics14010017","article-title":"A review of therapies for clostridioides difficile infection","volume":"14","author":"Morado","year":"2025","journal-title":"Antibiotics"},{"issue":"7","key":"10.1016\/j.idc.2025.07.007_bib5","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent clostridium difficile disease","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.idc.2025.07.007_bib6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cid\/civ994","article-title":"Establishing a fecal microbiota transplant service for the treatment of clostridium difficile infection","volume":"62","author":"Costello","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.07.007_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14712598.2022.2154600","article-title":"Microbiome therapeutics for the treatment of recurrent clostridioides difficile infection","volume":"23","author":"Bloom","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.idc.2025.07.007_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.anaerobe.2018.04.001","article-title":"Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent clostridium difficile infection","volume":"53","author":"Seekatz","year":"2018","journal-title":"Anaerobe"},{"issue":"10","key":"10.1016\/j.idc.2025.07.007_bib9","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/gutjnl-2018-317842","article-title":"Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent clostridioides difficile infection","volume":"68","author":"Mullish","year":"2019","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.idc.2025.07.007_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nrgastro.2016.98","article-title":"Understanding the mechanisms of faecal microbiota transplantation","volume":"13","author":"Khoruts","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"20","key":"10.1016\/j.idc.2025.07.007_bib11","doi-asserted-by":"crossref","first-page":"9352","DOI":"10.1073\/pnas.0913554107","article-title":"Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity againstClostridium difficile","volume":"107","author":"Rea","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.idc.2025.07.007_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1099\/jmm.0.000202","article-title":"Nisin is an effective inhibitor of clostridium difficile vegetative cells and spore germination","volume":"65","author":"Le Lay","year":"2016","journal-title":"J Med Microbiol"},{"issue":"1","key":"10.1016\/j.idc.2025.07.007_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/infdis\/jiae099","article-title":"Escape velocity\u2014the launch of microbiome therapies","volume":"230","author":"Kelly","year":"2024","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2025.07.007_bib14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA)","volume":"66","author":"Mcdonald","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2025.07.007_bib15","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA): 2021 focused update guidelines on management of clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2025.07.007_bib16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European society of clinical microbiology and infectious diseases: 2021 update on the treatment guidance document for clostridioides difficile infection in adults","volume":"27","author":"Van Prehn","year":"2021","journal-title":"Clin Microbiol Infection"},{"issue":"3","key":"10.1016\/j.idc.2025.07.007_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","article-title":"AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases","volume":"166","author":"Peery","year":"2024","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.idc.2025.07.007_bib18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/imj.13027","article-title":"Australasian society of infectious diseases updated guidelines for the management of clostridium difficile infection in adults and children in Australia and New Zealand","volume":"46","author":"Trubiano","year":"2016","journal-title":"Intern Med J"},{"issue":"6","key":"10.1016\/j.idc.2025.07.007_bib19","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.idc.2025.07.007_bib20","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.dld.2024.03.008","article-title":"Post-infectious ibs following clostridioides difficile infection; role of microbiota and implications for treatment","volume":"56","author":"Taghaddos","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.idc.2025.07.007_bib21","article-title":"Fecal microbiota transplantation for the treatment of recurrent clostridioides difficile (clostridium difficile)","volume":"4","author":"Minkoff","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.idc.2025.07.007_bib22","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s12275-024-00184-3","article-title":"Fecal microbiota transplantation: indications, methods, and challenges","volume":"62","author":"Lee","year":"2024","journal-title":"J Microbiol"},{"issue":"5","key":"10.1016\/j.idc.2025.07.007_bib23","first-page":"854","article-title":"Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis","volume":"44","author":"Eiseman","year":"1958","journal-title":"Surgery"},{"key":"10.1016\/j.idc.2025.07.007_bib24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jhin.2024.03.001","volume":"148","author":"Mullish","year":"2024","journal-title":"J Hosp Infect"},{"issue":"8354","key":"10.1016\/j.idc.2025.07.007_bib25","first-page":"845","article-title":"Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces","volume":"2","author":"Schwan","year":"1983","journal-title":"The Lancet (British edition)"},{"issue":"5","key":"10.1016\/j.idc.2025.07.007_bib26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent clostridium difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2025.07.007_bib27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MCG.0000000000001495","article-title":"Oral fecal microbiota transplant capsules are safe and effective for recurrent clostridioides difficile infection: a systematic review and meta-analysis","volume":"55","author":"Du","year":"2021","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.idc.2025.07.007_bib28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ajg.2013.59","article-title":"Fecal microbiota transplantation for clostridium difficile infection: systematic review and meta-analysis","volume":"108","author":"Kassam","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.idc.2025.07.007_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211041004","article-title":"Systematic review with meta-analysis: encapsulated faecal microbiota transplantation \u2013 evidence for clinical efficacy","volume":"14","author":"Cold","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"10.1016\/j.idc.2025.07.007_bib30","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/microorganisms9030548","article-title":"Ten-year follow-up of patients treated with fecal microbiota transplantation for recurrent clostridioides difficile infection from a randomized controlled trial and review of the literature","volume":"9","author":"Ooijevaar","year":"2021","journal-title":"Microorganisms"},{"issue":"10","key":"10.1016\/j.idc.2025.07.007_bib31","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1177\/2050640620957765","article-title":"Faecal microbiota transplantation for clostridioides difficile infection: four years\u2019 experience of The Netherlands donor feces bank","volume":"8","author":"Terveer","year":"2020","journal-title":"United European Gastroenterol J"},{"issue":"11","key":"10.1016\/j.idc.2025.07.007_bib32","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/cid\/cix1097","article-title":"Durability and long-term clinical outcomes of fecal microbiota transplant treatment in patients with recurrent clostridium difficile infection","volume":"66","author":"Mamo","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2025.07.007_bib33","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S2468-1253(22)00276-X","article-title":"Faecal microbiota transplantation for first or second clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Baunwall","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.idc.2025.07.007_bib34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/cid\/ciae467","article-title":"A randomized controlled trial of efficacy and safety of fecal microbiota transplant for preventing recurrent clostridioides difficile infection","volume":"80","author":"Drekonja","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.07.007_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/cid\/ciae468","article-title":"D\u00e9j\u00e0 vu: unanswered questions about fecal microbiota transplantation for recurrent clostridioides difficile infection","volume":"80","author":"Poutanen","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.07.007_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2024.10.032","article-title":"The new horizon of clostridioides difficile infection treatment","volume":"168","author":"Kuijper","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idc.2025.07.007_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241253089","article-title":"Microbiota restoration therapies for recurrent clostridioides difficile infection reach an important new milestone","volume":"17","author":"Dupont","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"10.1016\/j.idc.2025.07.007_bib38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1053\/j.gastro.2020.09.038","article-title":"Fecal microbiota transplantation is highly effective in real-world practice: initial results from the FMT national registry","volume":"160","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.idc.2025.07.007_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy045","article-title":"Is a single fecal microbiota transplant a promising treatment for recurrent clostridium difficile infection?","volume":"5","author":"Hota","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2025.07.007_bib41","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s10620-024-08351-7","article-title":"Successful treatment of recurrent clostridioides difficile infection using a novel, drinkable, oral formulation of fecal microbiota","volume":"69","author":"Sadowsky","year":"2024","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.idc.2025.07.007_bib42","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/MEG.0000000000001243","article-title":"Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent clostridium difficile infection: a systematic review and meta-analysis","volume":"30","author":"Khan","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.idc.2025.07.007_bib43","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.dld.2024.11.025","article-title":"Long-term stability and efficacy of frozen fecal microbiota transplant (FMT) product at 24 months","volume":"57","author":"Facchin","year":"2025","journal-title":"Dig Liver Dis"},{"issue":"8","key":"10.1016\/j.idc.2025.07.007_bib44","article-title":"Systematic review: adverse events of fecal microbiota transplantation","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.idc.2025.07.007_bib45","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gutjnl-2016-313017","article-title":"European consensus conference on faecal microbiota transplantation in clinical practice","volume":"66","author":"Cammarota","year":"2017","journal-title":"Gut"},{"issue":"21","key":"10.1016\/j.idc.2025.07.007_bib46","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.idc.2025.07.007_bib47","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/MPG.0000000000000281","article-title":"Fecal microbial transplantation in early-onset colitis: caution advised","volume":"61","author":"Vandenplas","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"8","key":"10.1016\/j.idc.2025.07.007_bib48","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/ajg.2013.164","article-title":"Norovirus gastroenteritis after fecal microbiota transplantation for treatment of clostridium difficile infection despite asymptomatic donors and lack of sick contacts","volume":"108","author":"Schwartz","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.idc.2025.07.007_bib51","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00161-21","article-title":"Fecal microbiota transplantation donor screening updates and research gaps for solid organ transplant recipients","volume":"60","author":"Mehta","year":"2022","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.idc.2025.07.007_bib52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/19490976.2017.1286006","article-title":"Challenges in fecal donor selection and screening for fecal microbiota transplantation: a review","volume":"8","author":"Woodworth","year":"2017","journal-title":"Gut Microbes"},{"issue":"12","key":"10.1016\/j.idc.2025.07.007_bib53","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.cmi.2017.05.015","article-title":"How to: establish and run a stool bank","volume":"23","author":"Terveer","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.idc.2025.07.007_bib54","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/cid\/ciz689","article-title":"Fecal microbiota transplantation for clostridioides difficile infection in immunocompromised hosts","volume":"72","author":"Revolinski","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2025.07.007_bib55","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/AOG.0000000000001911","article-title":"Fecal microbiota transplant for clostridium difficile infection in a pregnant patient","volume":"129","author":"Saeedi","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.idc.2025.07.007_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13216","article-title":"Successful treatment of fulminant clostridioides difficile infection with emergent fecal microbiota transplantation in a patient with acute myeloid leukemia and prolonged, severe neutropenia","volume":"22","author":"Lee","year":"2020","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.07.007_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14728214.2019.1591371","article-title":"Emerging drugs for the treatment of clostridium difficile","volume":"24","author":"Cammarota","year":"2019","journal-title":"Expet Opin Emerg Drugs"},{"key":"10.1016\/j.idc.2025.07.007_bib59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.anaerobe.2013.08.007","article-title":"Treatment approaches including fecal microbiota transplantation for recurrent clostridium difficile infection (RCDI) among infectious disease physicians","volume":"24","author":"Bakken","year":"2013","journal-title":"Anaerobe"},{"issue":"4","key":"10.1016\/j.idc.2025.07.007_bib60","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.chom.2022.03.016","article-title":"Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers","volume":"30","author":"Dsouza","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"12","key":"10.1016\/j.idc.2025.07.007_bib61","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1136\/gutjnl-2019-319548","article-title":"International consensus conference on stool banking for faecal microbiota transplantation in clinical practice","volume":"68","author":"Cammarota","year":"2019","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.idc.2025.07.007_bib62","article-title":"Extended screening costs associated with selecting donors for fecal microbiota transplantation for treatment of metabolic syndrome-associated diseases","volume":"4","author":"Laura","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.07.007_bib63","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2493901","article-title":"Fecal microbiota transplantation: a tale of two regulatory pathways","volume":"17","author":"Hoffmann","year":"2025","journal-title":"Gut Microbes"},{"key":"10.1016\/j.idc.2025.07.007_bib64","author":"Webb"},{"key":"10.1016\/j.idc.2025.07.007_bib65","unstructured":"Abreu MT, Schmitt SK, Lightdale J, et al. American Gastroenterological Association. Re: retention of access to conventional fecal microbiota transplantation for complicated and vulnerable patients with C. difficile infection. 2024. Available at: https:\/\/gastro.org\/news\/aga-calls-on-fda-to-retain-access-to-conventional-fmt\/."},{"issue":"7","key":"10.1016\/j.idc.2025.07.007_bib66","doi-asserted-by":"crossref","first-page":"e25023","DOI":"10.1002\/jcla.25023","article-title":"Assessment of faecal microbiota transplant stability in Deep-Freeze conditions: a 12-Month Ex Vivo viability analysis","volume":"38","author":"Soukupova","year":"2024","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"10.1016\/j.idc.2025.07.007_bib67","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1053\/j.gastro.2016.11.010","article-title":"Efficacy of sterile fecal filtrate transfer for treating patients with clostridium difficile infection","volume":"152","author":"Ott","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idc.2025.07.007_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/frmbi.2024.1399440","article-title":"Live biotherapeutic products: a capstone for prevention of recurrent clostridiodes difficile infection","volume":"3","author":"Sehgal","year":"2024","journal-title":"Front Microbiomes"},{"issue":"1","key":"10.1016\/j.idc.2025.07.007_bib69","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2412376","article-title":"Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products","volume":"16","author":"Kim","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.idc.2025.07.007_bib70","unstructured":"REBYOTA (fecal microbiota, live-jslm). [package insert]. Roseville, MN: Ferring pharmaceuticals; 2022. Available at: file:\/\/\/C:\/Users\/20572\/Downloads\/Ref70-Rebyota.pdf."},{"key":"10.1016\/j.idc.2025.07.007_bib71","unstructured":"Vowst (fecal microbiota spores, live-brpk). [package insert]. Cambridge, MA: Seres Therapeutics, Inc; 2024. Available at: file:\/\/\/C:\/Users\/20572\/Downloads\/Ref71-Vowst.pdf."},{"issue":"15","key":"10.1016\/j.idc.2025.07.007_bib72","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","article-title":"Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent clostridioides difficile infection","volume":"82","author":"Khanna","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.idc.2025.07.007_bib73","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/cid\/ciae437","article-title":"PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent clostridioides difficile infection","volume":"80","author":"Feuerstadt","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2025.07.007_bib74","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent clostridioides difficile infection","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.idc.2025.07.007_bib75","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.55758","article-title":"Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent clostridioides difficile infection: a phase 3, open-label, single-arm trial","volume":"6","author":"Sims","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"16","key":"10.1016\/j.idc.2025.07.007_bib76","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jama.2023.4314","article-title":"VE303, a defined bacterial consortium, for prevention of recurrent clostridioides difficile infection","volume":"329","author":"Louie","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.idc.2025.07.007_bib77","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2468-1253(21)00007-8","article-title":"The effect of a microbial ecosystem therapeutic (MET-2) on recurrent clostridioides difficile infection: a phase 1, open-label, single-group trial","volume":"6","author":"Kao","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"17","key":"10.1016\/j.idc.2025.07.007_bib78","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1001\/jama.2015.3725","article-title":"Administration of spores of nontoxigenic clostridium difficile strain M3 for prevention of recurrent C difficile infection: a randomized clinical trial","volume":"313","author":"Gerding","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.idc.2025.07.007_bib79","author":"Vedanta Biosciences"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:35:24Z","timestamp":1777577724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552025000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0891552025000704"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2025.07.007","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microbiome Therapeutics for Clostridioides difficile Infection","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2025.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}